PAR FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay? Paradigm has confirmed it will use a twice weekly dosage of 2mg/kg injectable pentosan polysulfate sodium in its Phase 3 trial. Jonathon Davidson 3 days ago ASX News Healthcare Biotechnology
DXB Dimerix begins recruiting young kidney disease patients in Mexico for Phase 3 Dimerix Limited (ASX:DXB) has confirmed it's begun recruiting adolescent kidney disease patients in Mexico, now that its first Phase 3 clinical trial location has been selected. Jonathon Davidson 12 Sep 2024 10:03 (AEST) ASX News Healthcare Biotechnology
BIT HotCopper users blunt as Biotron sinks -35%; long-awaited COVID drug results same as placebo Biotron (ASX:BIT) has angered shareholders on HotCopper on Friday as the results of its latest COVID-facing trial come up dusty. Jonathon Davidson 06 Sep 2024 13:04 (AEST) ASX News Healthcare Biotechnology
OCC Orthocell kicks off collagen-based dental bone repair product sales in Canada; eyeing next stop Brazil Orthocell (ASX:OCC) has confirmed its sold its first units of collagen-based bone repair product Striate+ in Canada through distro partner BioHorizons. Jonathon Davidson 06 Sep 2024 10:15 (AEST) ASX News Healthcare Biotechnology
IMU Imugene's azer-cel trial sees tumours temporarily disappear in 3 of 10 patients Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A @complete response’ in this case is a complete disappearance of all tumours. The company is focusing o... Jonathon Davidson 02 Sep 2024 10:14 (AEST) ASX News Healthcare Biotechnology
PYC PYC achieves key designation for drug aiming to treat blinding eye disease ADOA PYC Therapeutics Ltd has received a special designation from the FDA for its drug PYC-001 to treat a childhood-originating eye disease. Caroline Smith 30 Aug 2024 09:38 (AEST) ASX News Healthcare Biotechnology
TLX Telix wins fast track status from US FDA for new brain cancer PET scan imaging agent Telix Pharmaceuticals (ASX:TLX) has announced its receipt of fast track status from the US FDA within the approvals chain for the assessment of Telix's PET-scan brain cancer imaging agent Pixclara. Jonathon Davidson 28 Aug 2024 10:17 (AEST) ASX News Healthcare Steel Biotechnology Basic Materials
ACW Xanamem shows further depression improvements four weeks after 6-week treatment course Actinogen (ASX:ACW) has reported success in using its novel antidepressant Xanamem to mitigate the symptoms of major depression based on a daily 10mg dose. Jonathon Davidson 26 Aug 2024 10:36 (AEST) ASX News Healthcare Biotechnology
NOX Noxopharm aims for autoimmune market with first human trial of SOF-SKN Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions. Caroline Smith 19 Aug 2024 11:36 (AEST) ASX News Healthcare Biotechnology
NOX Noxopharm jumps 35% on news its drug CRO-67 reduced human pancreatic tumour cells in mice Shares in Noxopharm (ASX:NOX) jumped nearly 40% in morning trades on Wednesday as the company announced its experimental drug CRO-67 reduced human pancreatic tumour cells implanted into mice. Jonathon Davidson 14 Aug 2024 11:16 (AEST) ASX News Healthcare Biotechnology
IMM Immutep doses first human patient with IMP761 – a possible broad-ranging autoimmune treatment Immutep (ASX:IMM) has confirmed it's dosed the first human patient with its LAG-3 based autoimmune drug candidate IMP761. Jonathon Davidson 14 Aug 2024 09:22 (AEST) ASX News Healthcare Biotechnology
ACW Actinogen Medical weighs in on its latest results to market Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug's significant clinical and statistical benefits over a placebo in treating depression. Jonathon Davidson 13 Aug 2024 10:33 (AEST) ASX News Healthcare Biotechnology
CYP Cynata study shows efficacy of stem-cell therapy on chronic lung disease Cynata Therapeutics Ltd has published a study examining the effect of its Cymerus therapy on idiopathic pulmonary fibrosis symptoms. Caroline Smith 08 Aug 2024 12:51 (AEST) ASX News Healthcare Biotechnology